Grail, Inc. (GRAL)
GRAIL's Galleri Progresses While Back In Accumulation Levels
GRAL's Galleri test is easily its main value driver at this point. This test can screen over 50 cancers with high sensitivity and accuracy. Post-spin-off from Illumina, GRAL has continued growing its revenues while also securing partnerships like Quest Diagnostics and TRICARE. GRAL's Galleri also secured the FDA's Breakthrough Device status, and its pivotal PMA submission should happen by 1H2026.
How Does GRAIL Benefit From The Proposed MCED Legislation?
GRAIL, Inc.'s Galleri test could see significant revenue growth if the bipartisan MCED bill passes, enabling Medicare reimbursement for FDA-approved multi-cancer early detection tests. Galleri's potential market includes 67 million Medicare beneficiaries, with a conservative estimate of $2.4 billion in revenue by the fifth year post-legislation. Despite promising financials and market leadership, Galleri's FDA approval is pending, and Medicare reimbursement may not start until 2028, posing short-term risks.
GRAIL, Inc. (GRAL) Q4 2024 Earnings Call Transcript
GRAIL, Inc. (NASDAQ:GRAL ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Bob Ragusa - Chief Executive Officer and Board Member Aaron Freidin - Chief Financial Officer Joshua Ofman - President Sir Harpal Kumar - President of International Business and BioPharma Conference Call Participants Doug Schenkel - Wolfe Research Operator Good day, ladies and gentlemen, and welcome to the GRAIL Fourth Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode.
Watch These Grail Price Levels After Med Tech Company's Stock Soared 64% Last Week
Grail (GRAL) shares could remain in focus after surging to a new record high on Friday to cap off a huge week of gains amid optimism about the medical technology company's early-detection cancer screening blood tests.
GRAIL: Biotech Stock Targeting $100B Cancer Market
GRAIL NASDAQ: GRAL is a small-cap biotechnology company that has gone on a very strong run over the last month and a half. Shares of the healthcare stock are up 58% since Oct. 24, as of the Dec. 11 close.
World's biggest hedge fund flags the ‘holy grail' that may shield investors if U.S. stock rally crumbles
Karen Karniol-Tambour, co-chief investment officer at Bridgewater Associates, says valuations are much higher for U.S. stocks than they were when the bull run began.
GRAIL Inc. (GRAL) Q3 2024 Earnings Call Transcript
GRAIL Inc. (NASDAQ:GRAL ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Robert Ragusa - CEO & Director Aaron Freidin - Chief Financial Officer Joshua Ofman - President Harpal Kumar - President, International Business and BioPharma Conference Call Participants Operator Good day, ladies and gentlemen, and welcome to the GRAIL Third Quarter 2024 Earnings Call. [Operator Instructions] Please be advised that this conference call is being recorded.
GRAIL's Potential Turnaround: Seeking FDA Approval For Galleri
Grail's Galleri test detects over 50 cancer types early, potentially saving lives, and is progressing towards FDA approval and broader insurance coverage. The company, a spinoff from Illumina, has significant backing and aims to reduce costs while expanding its market presence and regulatory validation. Despite high cash burn, Grail's strong cash reserves and strategic focus on FDA approval and Medicare reimbursement present substantial upside potential.
2 Spinoff Stocks Down 16%. Should You Buy Now?
Stock spinoffs are a popular corporate strategy for unlocking shareholder value, but one that rarely pays off for investors.
GRAIL Inc. (GRAL) Q2 2024 Earnings Call Transcript
GRAIL Inc. (NASDAQ:GRAL ) Q2 2024 Results Conference Call August 13, 2024 4:30 PM ET Company Participants Bob Ragusa - CEO & Director Aaron Freidin - Chief Financial Officer Joshua Ofman - President Conference Call Participants Tejas Savant - Morgan Stanley Sung Ji Nam - Scotiabank Operator Good day, ladies and gentlemen, and welcome to the GRAIL Second Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode.
Grail to cut jobs, planned hires for 2024 by about 30%
Cancer test maker Grail said on Tuesday it would reduce existing headcount and planned hires for 2024 by about 30%, as part of its restructuring program.
3 Top Cancer Treatment Stocks to Buy Now
Discovering and developing a cancer drug that can treat many types of the disease can be extremely lucrative. Consider that one such drug, Merck's (NYSE: MRK ) Keytruda, generated $25 billion in revenue for the pharmaceutical giant last year.
